A study published in Nature Medicine found that the high vaccination rate of the new coronary pneumonia (COVID-19) vaccine is related to the low infection rate of the new coronavirus (SARS-CoV-2) in people aged 16 and under
Clinical trials and vaccination plans show that Pfizer-BioNTech's new coronary pneumonia vaccine is effective in preventing infection and morbidity at the individual and community levels
Israel began vaccination on December 19, 2020, and covered nearly 50% of the population within 9 weeks
The authors reminded that their results did not consider the population's natural immunity to SARS-CoV-2
Related paper information: https://doi.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.